CO2017011238A2 - Anticuerpos anti-c1s humanizados - Google Patents
Anticuerpos anti-c1s humanizadosInfo
- Publication number
- CO2017011238A2 CO2017011238A2 CONC2017/0011238A CO2017011238A CO2017011238A2 CO 2017011238 A2 CO2017011238 A2 CO 2017011238A2 CO 2017011238 A CO2017011238 A CO 2017011238A CO 2017011238 A2 CO2017011238 A2 CO 2017011238A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- humanized anti
- present description
- description provides
- nucleic acids
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21106—Hepsin (3.4.21.106)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente descripción proporciona anticuerpos anti-C1s humanizados. La presente descripción proporciona ácidos nucleicos que comprenden secuencias de nucleótidos que codifican los anticuerpos anti-C1s humanizados; y las células hospedadoras que comprenden los ácidos nucleicos. La presente descripción proporciona composiciones que comprenden los anticuerpos anti-C1s humanizados. La presente descripción proporciona métodos de uso de los anticuerpos anti-C1s humanizados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562143636P | 2015-04-06 | 2015-04-06 | |
US201562200997P | 2015-08-04 | 2015-08-04 | |
PCT/US2016/026038 WO2016164358A1 (en) | 2015-04-06 | 2016-04-05 | Humanized anti-c1s antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017011238A2 true CO2017011238A2 (es) | 2018-01-16 |
Family
ID=57073330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0011238A CO2017011238A2 (es) | 2015-04-06 | 2017-10-31 | Anticuerpos anti-c1s humanizados |
Country Status (27)
Country | Link |
---|---|
US (3) | US10729767B2 (es) |
EP (2) | EP4212175A1 (es) |
JP (3) | JP7005483B2 (es) |
KR (1) | KR20180006379A (es) |
CN (2) | CN108348598B (es) |
AU (2) | AU2016246452B2 (es) |
BR (1) | BR112017021289A2 (es) |
CA (1) | CA2981321A1 (es) |
CL (1) | CL2017002514A1 (es) |
CO (1) | CO2017011238A2 (es) |
DK (1) | DK3280440T3 (es) |
EA (1) | EA201792080A1 (es) |
ES (1) | ES2938359T3 (es) |
FI (1) | FI3280440T3 (es) |
HK (2) | HK1250930A1 (es) |
HR (1) | HRP20230093T1 (es) |
HU (1) | HUE061076T2 (es) |
IL (2) | IL298180A (es) |
LT (1) | LT3280440T (es) |
MX (2) | MX2017012834A (es) |
PH (1) | PH12017501815A1 (es) |
PL (1) | PL3280440T3 (es) |
PT (1) | PT3280440T (es) |
RS (1) | RS63956B1 (es) |
SG (2) | SG10201909180SA (es) |
SI (1) | SI3280440T1 (es) |
WO (1) | WO2016164358A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
JP6543572B2 (ja) | 2012-11-02 | 2019-07-10 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体C1s抗体とそれらの用途 |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
RS63956B1 (sr) | 2015-04-06 | 2023-02-28 | Bioverativ Usa Inc | Humanizovana anti-c1s antitela i metode njihove upotrebe |
MX2019004259A (es) * | 2016-10-12 | 2019-09-27 | Bioverativ Usa Inc | Anticuerpos anti-c1s y metodos de uso de los mismos. |
US20210198347A1 (en) * | 2018-04-13 | 2021-07-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-complement component antibodies and methods of use |
WO2022031978A1 (en) | 2020-08-06 | 2022-02-10 | Bioverativ Usa Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
EP4313296A1 (en) | 2021-03-31 | 2024-02-07 | Bioverativ USA Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
EP4337332A2 (en) | 2021-07-13 | 2024-03-20 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS60192263A (ja) | 1984-03-13 | 1985-09-30 | Teijin Ltd | 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法 |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
DE69429816T2 (de) | 1993-09-01 | 2002-09-19 | Sanquin Bloedvoorziening | C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt |
DK0797676T3 (da) | 1993-10-25 | 2006-04-18 | Canji Inc | Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf |
NZ296581A (en) | 1994-12-09 | 2000-02-28 | Imp College Innovations Ltd | A method of identifying genes identified in a microorganisms ability to adapt to changes in its environment |
US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
WO2000047194A2 (en) | 1999-02-09 | 2000-08-17 | 3-Dimensional Pharmaceuticals, Inc. | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
WO2000064327A2 (en) | 1999-04-26 | 2000-11-02 | Duke University | Inhibition of complement action |
WO2001013945A1 (en) | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
PT1252184E (pt) | 2000-01-31 | 2008-04-15 | Pharming Intellectual Pty Bv | Inibidor humano c1 produzido no leite de mamíferos transgénicos |
US6998468B2 (en) | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
US7071299B2 (en) | 2000-06-21 | 2006-07-04 | Zymogenetics, Inc. | Peptide and polypeptide inhibitors of complement C1s |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
JP2004536138A (ja) | 2001-07-26 | 2004-12-02 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 認識機能を改善する方法 |
US20080206242A1 (en) * | 2002-03-01 | 2008-08-28 | Xencor, Inc. | Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies |
SE0202880D0 (sv) | 2002-07-26 | 2002-09-30 | Wieslab Ab | Complement system deficiency assay |
US7666627B2 (en) | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
WO2004022096A1 (en) | 2002-09-06 | 2004-03-18 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
CN1787741B (zh) | 2003-05-15 | 2011-08-17 | 唐纳士公司 | 用于预防和治疗败血症的方法与组合物 |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
WO2005025509A2 (en) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
AU2003271186A1 (en) | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
PL1753456T3 (pl) | 2004-06-10 | 2017-01-31 | Omeros Corporation | Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2 |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1819731A4 (en) | 2004-12-08 | 2013-02-13 | Immunomedics Inc | METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER |
ATE450522T1 (de) | 2005-03-16 | 2009-12-15 | Janssen Pharmaceutica Nv | Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden |
EP2529746A1 (en) | 2005-06-06 | 2012-12-05 | Girish J. Kotwal | Methods for treatment or prophylaxis of reperfusion injury |
AU2006304804B2 (en) | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
US9480658B2 (en) | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
US8148330B2 (en) | 2005-12-09 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
KR101508668B1 (ko) | 2005-12-21 | 2015-04-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | 허혈-재관류 손상의 예방을 위한 c1 억제제의 용도 |
FR2897868B1 (fr) | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii. |
PL2596807T3 (pl) | 2006-03-08 | 2016-06-30 | Archemix Llc | Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych |
EP2061810B1 (en) | 2006-09-05 | 2014-11-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
PL2698166T3 (pl) | 2006-10-10 | 2016-03-31 | Regenesance B V | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
EP2114870B1 (en) | 2006-12-19 | 2019-07-03 | Versitech Limited | Synthetic ion channels |
PL2148691T3 (pl) | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
JP5469600B2 (ja) | 2007-07-16 | 2014-04-16 | ジェネンテック, インコーポレイテッド | 抗CD79b抗体及びイムノコンジュゲートとその使用方法 |
US8236307B2 (en) | 2007-08-03 | 2012-08-07 | Genentech, Inc. | Humanized anti-FGF19 antagonists and methods using same |
EP2278987A4 (en) | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
WO2009132058A2 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
WO2009151634A1 (en) | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
EP2894165B1 (en) | 2008-11-10 | 2023-01-04 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
CN105866426B (zh) | 2008-12-01 | 2018-11-23 | 小利兰·斯坦福大学托管委员会 | 用于检测补体结合性抗体的方法和组合物 |
US8401799B2 (en) | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
CN102597005A (zh) | 2009-06-23 | 2012-07-18 | 阿雷克森制药公司 | 与补体蛋白质结合的双特异性抗体 |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
BR112012008970A2 (pt) | 2009-10-16 | 2019-12-10 | Omeros Corp | uso de uma composição, e, composição |
JP5851391B2 (ja) | 2010-02-16 | 2016-02-03 | 国立大学法人京都工芸繊維大学 | 抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用 |
AU2011223866B2 (en) | 2010-03-01 | 2015-05-21 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating Degos' disease |
NZ629829A (en) | 2010-04-30 | 2015-11-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
CA2799746C (en) | 2010-05-17 | 2020-11-24 | Sai Reddy | Rapid isolation of monoclonal antibodies from animals |
MX2012014975A (es) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Anticuerpos al fragmento c3d de componente 3 de complemento. |
WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
SG190938A1 (en) | 2010-12-06 | 2013-07-31 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use of same to treat cancer |
MX355648B (es) | 2011-04-08 | 2018-04-26 | Univ Leicester | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. |
HUE049154T2 (hu) | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
US9289467B2 (en) | 2011-08-10 | 2016-03-22 | Case Western Reserve University | Compositions and methods for treating bone conditions |
US9452203B2 (en) | 2011-12-22 | 2016-09-27 | Csl Behring Gmbh | Use of C1-inhibitor for the treatment of secondary edema of the central nervous system |
JP6081699B2 (ja) | 2011-12-28 | 2017-02-15 | 雅史 溝上 | Il−28bの分析方法 |
EP3722320A3 (en) * | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
JP6543572B2 (ja) * | 2012-11-02 | 2019-07-10 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体C1s抗体とそれらの用途 |
CA2899589C (en) | 2013-01-31 | 2022-02-22 | Seoul National University R & Db Foundation | C5 antibody and method for preventing and treating complement-related diseases |
JP6462680B2 (ja) | 2013-07-09 | 2019-01-30 | アネクソン,インコーポレーテッド | 抗補体因子C1q抗体及びその使用 |
WO2015084999A1 (en) | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
RS63956B1 (sr) | 2015-04-06 | 2023-02-28 | Bioverativ Usa Inc | Humanizovana anti-c1s antitela i metode njihove upotrebe |
AU2016282782A1 (en) | 2015-06-26 | 2018-01-18 | Bioverativ Usa Inc. | Methods of treating autoimmune and alloimmune disorders |
MX2019004259A (es) | 2016-10-12 | 2019-09-27 | Bioverativ Usa Inc | Anticuerpos anti-c1s y metodos de uso de los mismos. |
US20210115116A1 (en) | 2017-03-14 | 2021-04-22 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases and disorders |
-
2016
- 2016-04-05 RS RS20230104A patent/RS63956B1/sr unknown
- 2016-04-05 FI FIEP16777134.4T patent/FI3280440T3/fi active
- 2016-04-05 WO PCT/US2016/026038 patent/WO2016164358A1/en active Application Filing
- 2016-04-05 DK DK16777134.4T patent/DK3280440T3/da active
- 2016-04-05 ES ES16777134T patent/ES2938359T3/es active Active
- 2016-04-05 CN CN201680032952.9A patent/CN108348598B/zh active Active
- 2016-04-05 US US15/564,904 patent/US10729767B2/en active Active
- 2016-04-05 CN CN202311019350.8A patent/CN117285634A/zh active Pending
- 2016-04-05 EP EP22207626.7A patent/EP4212175A1/en active Pending
- 2016-04-05 SG SG10201909180S patent/SG10201909180SA/en unknown
- 2016-04-05 LT LTEPPCT/US2016/026038T patent/LT3280440T/lt unknown
- 2016-04-05 PL PL16777134.4T patent/PL3280440T3/pl unknown
- 2016-04-05 IL IL298180A patent/IL298180A/en unknown
- 2016-04-05 AU AU2016246452A patent/AU2016246452B2/en active Active
- 2016-04-05 PT PT167771344T patent/PT3280440T/pt unknown
- 2016-04-05 SI SI201631662T patent/SI3280440T1/sl unknown
- 2016-04-05 EP EP16777134.4A patent/EP3280440B1/en active Active
- 2016-04-05 JP JP2018503727A patent/JP7005483B2/ja active Active
- 2016-04-05 HR HRP20230093TT patent/HRP20230093T1/hr unknown
- 2016-04-05 HU HUE16777134A patent/HUE061076T2/hu unknown
- 2016-04-05 KR KR1020177032117A patent/KR20180006379A/ko not_active Application Discontinuation
- 2016-04-05 BR BR112017021289A patent/BR112017021289A2/pt active Search and Examination
- 2016-04-05 EA EA201792080A patent/EA201792080A1/ru unknown
- 2016-04-05 CA CA2981321A patent/CA2981321A1/en active Pending
- 2016-04-05 IL IL254670A patent/IL254670B2/en unknown
- 2016-04-05 MX MX2017012834A patent/MX2017012834A/es unknown
- 2016-04-05 SG SG11201707886WA patent/SG11201707886WA/en unknown
-
2017
- 2017-10-03 PH PH12017501815A patent/PH12017501815A1/en unknown
- 2017-10-05 CL CL2017002514A patent/CL2017002514A1/es unknown
- 2017-10-05 MX MX2022001085A patent/MX2022001085A/es unknown
- 2017-10-31 CO CONC2017/0011238A patent/CO2017011238A2/es unknown
-
2018
- 2018-08-14 HK HK18110393.2A patent/HK1250930A1/zh unknown
-
2019
- 2019-01-30 HK HK19101609.0A patent/HK1259251A1/zh unknown
-
2020
- 2020-06-11 US US16/898,908 patent/US11246926B2/en active Active
- 2020-09-28 JP JP2020161908A patent/JP7153696B2/ja active Active
-
2022
- 2022-03-07 JP JP2022034295A patent/JP2022078221A/ja active Pending
- 2022-05-30 AU AU2022203679A patent/AU2022203679A1/en active Pending
- 2022-08-10 US US17/818,885 patent/US20230218753A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017011238A2 (es) | Anticuerpos anti-c1s humanizados | |
ECSP19026178A (es) | Anticuerpos anti-pd-1 y sus usos | |
ECSP19050049A (es) | Anticuerpos anti-ox40 y sus usos | |
CO2017005842A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
CO2017011957A2 (es) | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas | |
CO2018006301A2 (es) | Mutantes de proteína f de rsv | |
ECSP18094829A (es) | Anticuerpos anti-cd40 y sus usos | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
CR20150462A (es) | Inhibidores de erk y sus usos | |
CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
BR112018008051A2 (pt) | vacinas de ácido nucleico para vírus de varicella zoster (vzv) | |
AR103225A1 (es) | Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican | |
BR112017012679A2 (pt) | compostos imunomoduladores, seus usos, composição e kit | |
BR112018004965A2 (pt) | domínios de superfamìlia de imunoglobulina variante ajustàvel | |
EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
CL2019000975A1 (es) | Anticuerpos anti-c1s y métodos de uso de los mismos | |
WO2014145870A3 (en) | Novel compositions, methods and kits for blood typing | |
CL2020001137A1 (es) | Anticuerpos anti-apoc3 y métodos de uso de estos. | |
AR103294A1 (es) | Composiciones y procedimientos para la glicosilación de proteínas | |
CL2017001172A1 (es) | Anticuerpos anti-interleukin-33 y sus usos |